RXP 407: inhibits angiotensin I converting enzyme [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 9827219 |
| CHEMBL ID | 1235767 |
| MeSH ID | M0304174 |
| Synonym |
|---|
| CHEMBL1235767 , |
| cid 9827219 |
| n~2~-acetyl-n-{(1r)-1-[(s)-[(2s)-3-{[(2s)-1-amino-1-oxopropan-2-yl]amino}-2-methyl-3-oxopropyl](hydroxy)phosphoryl]-2-phenylethyl}-l-alpha-asparagine |
| rx4 , |
| bdbm50393213 |
| rxp-407 |
| rxp 407 |
| gtpl7894 |
| (3s)-3-acetamido-4-[[(1r)-1-[[(2s)-3-[[(2s)-1-amino-1-oxopropan-2-yl]amino]-2-methyl-3-oxopropyl]-hydroxyphosphoryl]-2-phenylethyl]amino]-4-oxobutanoic acid |
| ac-asp-(l)phe(po2ch2)(l)ala-ala-nh2; rxp407 |
| Q27088653 |
| 237770-41-1 |
| AKOS040749377 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | Ki | 3.7535 | AID689966; AID689967 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID689966 | Inhibition of human ACE N-terminal domain expressed in CHO cells after 90 mins by fluorescence assay | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 ISSN: 1520-4804 | Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry. |
| AID689967 | Inhibition of human ACE C-terminal domain expressed in CHO cells after 90 mins by fluorescence assay | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 ISSN: 1520-4804 | Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry. |
| AID1345457 | Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2)) | 2012 | Biological chemistry, May, Volume: 393, Issue:6 ISSN: 1437-4315 | New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| acetohydroxamic acid | acetohydroxamic acids; carbohydroximic acid | algal metabolite; EC 3.5.1.5 (urease) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| alendronate | 1,1-bis(phosphonic acid); primary amino compound | bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| incadronate | 1,1-bis(phosphonic acid) | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | ||
| pamidronate | phosphonoacetic acid | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| risedronic acid | pyridines | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| fosinoprilat | L-proline derivative; phosphinic acids | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| zoledronic acid | 1,1-bis(phosphonic acid); imidazoles | bone density conservation agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| alafosfalin | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |||
| fosinopril | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|